Clinical significance of preoperative inflammatory markers in non-small cell lung cancer patients: A multicenter retrospective study.
Adult
Aged
Aged, 80 and over
Biomarkers
/ blood
Blood Cell Count
Blood Platelets
/ immunology
C-Reactive Protein
/ analysis
Carcinoma, Non-Small-Cell Lung
/ blood
Disease-Free Survival
Female
Humans
Inflammation
/ blood
Japan
/ epidemiology
L-Lactate Dehydrogenase
/ blood
Lung Neoplasms
/ blood
Lymphocytes
/ immunology
Male
Middle Aged
Monocytes
/ immunology
Neoplasm Staging
Pneumonectomy
Preoperative Period
Prognosis
ROC Curve
Retrospective Studies
Risk Factors
Serum Albumin, Human
/ analysis
Smoking
/ blood
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
16
06
2020
accepted:
18
10
2020
entrez:
2
11
2020
pubmed:
3
11
2020
medline:
29
12
2020
Statut:
epublish
Résumé
Inflammatory biomarkers have been associated with clinical outcomes in non-small cell lung cancer (NSCLC). However, the best prognostic marker(s) has not been identified, and the association between inflammatory markers and clinical characteristics is poorly understood. We selected 1,237 patients with resected NSCLC from Kyushu University (2003-2015) and Kyushu Cancer Center (2009-2015) in Japan. Pearson product-moment correlation coefficient among inflammatory markers and area under curve (AUC) of receiver operating characteristic (ROC) curve analyses for overall survival (OS) were calculated. We analyzed the associations between inflammatory markers and clinical factors using Student's t-test. Univariate and multivariate analyses with Cox proportional hazards regression analyses were performed to evaluate the relationship between survival and clinical factors. The cut-off values for neutrophil-lymphocyte ratio (NLR), lymphocyte-monocyte ratio (LMR), platelet-lymphocyte ratio, and derived NLR (dNLR) were determined by ROC curve analyses for OS. We found a strong positive correlation between NLR and dNLR (r = 0.9629). The AUC of LMR was the highest amongst the measured metrics, and the AUC of NLR was higher than dNLR. Levels of some inflammatory markers were associated with sex, smoking, squamous cell carcinoma, and pathological stage. LMR ≥ 5.11 and lactate dehydrogenase (LDH) concentration ≥ 222 (U/L) were independent predictors of both disease-free survival (DFS) and OS (LMR; P = 0.0009 and 0.0008, LDH; P = 0.0195 and 0.0187, respectively). Certain inflammatory markers, potentially linked to smoking, were associated with an advanced pathological stage in NSCLC. LMR and LDH were independent predictors of both DFS and OS.
Identifiants
pubmed: 33137158
doi: 10.1371/journal.pone.0241580
pii: PONE-D-20-18417
pmc: PMC7605706
doi:
Substances chimiques
Biomarkers
0
C-Reactive Protein
9007-41-4
L-Lactate Dehydrogenase
EC 1.1.1.27
Serum Albumin, Human
ZIF514RVZR
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0241580Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Thorac Oncol. 2007 Aug;2(8):706-14
pubmed: 17762336
Med Oncol. 2014 Jul;31(7):70
pubmed: 24927957
Cancer Invest. 2016 Sep 13;34(8):378-84
pubmed: 27558529
J Thorac Dis. 2016 Dec;8(12):3658-3666
pubmed: 28149561
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Lancet. 2017 Jan 21;389(10066):255-265
pubmed: 27979383
Ann Thorac Cardiovasc Surg. 2020 Oct 21;26(5):248-255
pubmed: 32074540
Cancer Res. 2013 Apr 15;73(8):2381-8
pubmed: 23580578
Clin Lung Cancer. 2020 Jul;21(4):365-377.e5
pubmed: 32245624
Tumour Biol. 2016 Apr;37(4):5285-93
pubmed: 26561466
J Thorac Oncol. 2011 Jul;6(7):1229-35
pubmed: 21610521
Eur J Cardiothorac Surg. 2014 Jan;45(1):108-13
pubmed: 23711463
Cancer Epidemiol Biomarkers Prev. 2014 Dec;23(12):2965-70
pubmed: 25392179
JAMA Oncol. 2018 Mar 1;4(3):351-357
pubmed: 29327044
Semin Thorac Cardiovasc Surg. 2019 Apr 19;:
pubmed: 31009697
Cell. 2008 Sep 5;134(5):703-7
pubmed: 18775299
Lancet. 2016 Apr 9;387(10027):1540-1550
pubmed: 26712084
J Thorac Oncol. 2015 Jan;10(1 Suppl 1):S1-63
pubmed: 25535693
Sci Rep. 2016 Oct 05;6:34823
pubmed: 27703265
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
PLoS One. 2014 Oct 02;9(9):e108062
pubmed: 25275631
Surg Oncol. 2018 Mar;27(1):88-94
pubmed: 29549910
J Thorac Cardiovasc Surg. 2013 Jul;146(1):24-30
pubmed: 23398645
JAMA Oncol. 2019 Jul 25;:
pubmed: 31343662
Mol Cancer Ther. 2015 Apr;14(4):847-56
pubmed: 25695955
J Natl Compr Canc Netw. 2010 Jul;8(7):740-801
pubmed: 20679538
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
J Clin Oncol. 2003 Apr 1;21(7):1232-7
pubmed: 12663709
Nature. 2008 Jul 24;454(7203):436-44
pubmed: 18650914
Cancer Res. 2006 Dec 1;66(23):11238-46
pubmed: 17114237
J Thorac Oncol. 2016 Aug;11(8):1311-1318
pubmed: 27234603
Arch Pathol Lab Med. 2009 Apr;133(4):628-32
pubmed: 19391664
Sci Rep. 2015 Apr 22;5:9800
pubmed: 25902419
J Thorac Oncol. 2016 Nov;11(11):1879-1890
pubmed: 27346415
Lancet. 2016 Apr 30;387(10030):1837-46
pubmed: 26970723
Cell Physiol Biochem. 2018;45(3):951-961
pubmed: 29428948
Asia Pac J Clin Oncol. 2020 Feb;16(1):63-69
pubmed: 31721468
PLoS One. 2016 Oct 3;11(10):e0163397
pubmed: 27695079
World J Oncol. 2019 Feb;10(1):35-45
pubmed: 30834050
PLoS One. 2015 Aug 27;10(8):e0136252
pubmed: 26313661
Clin Lung Cancer. 2018 Mar;19(2):120-129
pubmed: 29153898
J Cell Physiol. 2018 Oct;233(10):6337-6343
pubmed: 29672849
Nat Rev Cancer. 2012 Mar 22;12(4):252-64
pubmed: 22437870
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
Lung Cancer. 2018 Oct;124:179-188
pubmed: 30268458
Clin Cancer Res. 2014 Jul 1;20(13):3613-22
pubmed: 24803578
J Thorac Oncol. 2018 Jan;13(1):97-105
pubmed: 29170120